Beijing Wantai Biological Pharmacy Enterprise Third Quarter 2024 Earnings: Misses Expectations

Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥582.1m (down 28% from 3Q 2023).
• Net income: CN¥6.17m (down 94% from 3Q 2023).
• Profit margin: 1.1% (down from 13% in 3Q 2023).
• EPS: CN¥0.005 (down from CN¥0.085 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Wantai Biological Pharmacy Enterprise Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 95%.

Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 5.1% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Beijing Wantai Biological Pharmacy Enterprise's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.